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Parathyroid and bone response of the diabetic patient to uremia.
Biochemical and radiologic indices of bone disease were assessed in 26
insulin-dependent diabetic patients and 28 nondiabetic patients with
endstage kidney disease. The two groups were comparable in age, sex,
duration of renal failure, and length of time on dialysis. Diabetic
patients showed significantly lower serum calcium and immunoreactive
parathyroid hormone (iPTH) levels than nondiabetic patients. iPTH
was not related to total serum calcium, but was positively correlated
with serum phosphorous (r = 0.37, P < 0.05 and r = 0.54, P < 0.005, in
nondiabetic and diabetic patients, respectively). iPTH correlated with
alkaline phosphatase (r = 0.59, P < 0.0009) and calcitonin (r = 0.51, P
< 0.05) only in nondiabetic patients. Osteitis fibrosa was noted radio-
logically in 30% of nondiabetic patients and in none of the diabetic
patients (P < 0.03). Bone morphology in eight diabetic patients who
underwent iliac bone biopsy was characterized by reduced trabecular
and osteoid bone volume, no woven bone, and marked reduction in
indices of bone formation and resorption. The small amount of bone and
lack of osteomalacia are a unique feature of the diabetic patient with
chronic renal disease. The long-term sequelae of low bone turnover and
reduced circulating iPTH may present a special problem to the long
term diabetic survivor on the current therapies of uremia.
Réponses parathyroIdienne et osseuse de malades diabétiques en uré-
mie. Les indices biochimiques et radiologiques d'ostéopathie ont été
déterminés chez 26 malades diabétiques insulino-dépendants et 28
malades nondiabetiques avec une néphropathie terminale. Les deux
groupes étaient comparables en age, sexe, durée de l'insuffisance
rénale, et durée de Ia dialyse. Les malades diabétiques avaient un
calcium sérique et une hormone parathyroidienne immuno-réactive
(iPTH) significativement plus faibles que les malades nondiabétiques.
iPTH n'était pas reliée au calcium sérique total, mais était positivement
corrélée avec le phosphore sérique (r = 0,37, P < 0,05 et r = 0,54, P <
0,005, chez les nondiabétiques et les diabétiques, respectivement).
iPTH était corrélée a Ia phosphatase alcaline (r = 0,59, P < 0,0009) et a
Ia calcitonine (r = 0,51, P < 0,05) uniquement chez les malades
nondiabétiques. Une ostéIte fibreuse a été notée radiologiquement chez
30% des malades nondiabétiques et chez aucun des diabetiques (P <
0,03). La morphologie osseuse chez huit diabétiques qui avaient subi
une biopsie de Ia crete iliaque était caractérisée par une reduction des
volumes osseux trabéculaire et ostéoIde, I'absence d'os spongieux, et
une reduction marquee des indices de formation et de resorption
osseuses. La faible quantité d'os et l'absence d'ostéomalacie sont une
caractéristique unique du malade diabetique atteint de nephropathie
chronique. Les séquelles a long terme d'un renouvellement osseux
faible et d'une diminution d'iPTH circulante pourraient constituer un
probléme special pour le diabetique survivant a long terme avec les
traitements habituels de I'urémie.
Diabetes mellitus results in pathologic changes and functional
derangements in many organs. Several abnormalities have been
described in the skeleton of patients with insulin-dependent
type I and noninsulin-dependent type II diabetes [1—7]. Howev-
er, the consequences of these abnormalities are not clear [2, 8].
The development of diabetic nephropathy and renal failure adds
another dimension to the bone pathology. We and other investi-
gators have noted reduced secondary hyperparathyroidism in
diabetic patients on hemodialysis and a lower incidence of
aseptic necrosis following transplantation [9, 10]. The present
study was undertaken to further characterize the mineral me-
tabolism and to determine the relationship of PTH to static and
dynamic indices of bone histology in the uremic diabetic
patient. Several features of metabolic bone disease which
appear to be unique to the diabetic patient with endstage renal
disease prompt this report.
Methods
Fifty-four patients with renal failure referred for kidney
transplantation were selected for this study. None of the
patients had undergone parathyroidectomy or were on cimeti-
dine or vitamin D therapy. Nondiabetic patients did not have
overt carbohydrate intolerance and remained euglycemic on
glucocorticoids after kidney transplantation. The diabetic pa-
tients had insulin-dependent diabetes for over 20 years and
continued to require insulin in renal failure. Since diabetic
nephropathy is characterized by a brief duration of renal failure
[11], diabetic and nondiabetic patients were selected for this
study with the following criteria: (1) the course of the renal
failure documented to have been less than 5 years; (2) renal
disease characterized by proteinuria and hypertension.
Serum immunoreactive parathyroid hormone (iPTH) was
measured by the method of Arnaud, Tsao, and Littledike [12].
The assay uses an antiserum (GP-1M) with major specificity for
the carboxyl terminal region of the PTH molecule, quantitating
both intact species of circulating hormone and fragments.
Calcitonin was measured in plasma by the method of Heath and
Sizemore [13], and 25 hydroxyvitamin D [14], and 1,25 dihy-
droxyvitamin D [15] in serum by competitive protein binding
assays following the isolation of the metabolite by chromatogra-
phy. Total calcium and magnesium were measured by atomic
absorption spectrometry, phosphorous by the standard Sub-
barow method, and albumin and alkaline phosphatase by the
autoanalyzer.
Conventional screen-film radiography was performed on all
subjects and included radiographs of the thoracic and lumbar
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spine, chest, abdomen, and pelvis. Radiographs of the hands
were not obtained. The radiographs for each subject were
reviewed in composite and without access to clinical data.
Radiographic findings of osteopenia, osteosclerosis, and oste-
iris fibrosa were evaluated as follows:
• Osteopenia was determined radiographically by general-
ized radiolucency of the skeleton, accentuation of primary
trabeculae, and biconcave or wedged deformities of the
vertebral bodies.
• Osteoscierosis was determined radiographically by general-
ized increase in radiodensity, coarse thickening of trabecu-
lae, and radiodense bands paralleling the endplate of the
vertebral bodies.
• Osteitis fibrosa was defined radiographically by subperios-
teal bone resorption at sites of musculotendinous insertions
such as the coracoclavicular ligaments, or by subchondral
bone resorption at articular sites such as the sacroiliac
joints, symphysis, or acromioclavicular joints.
Transilial bone biopsies were performed after double tetracy-
cline labelling at the time of renal transplantation in eight
consecutive diabetic patients using the Bordier trephine, 8 mm
in diameter. The specimens were taken from a standard area 2
cm below and posterior to the anterior iliac spine from the inner
table of the pelvis. The core of bone was placed in Mellonigs
fixative or 70% ethanol and sent without delay to the Depart-
ment of Medicine, Omaha, Nebraska. After dehydration and
defatting by successive changes of alcohol and acetone, the
specimens were embedded in methyl methacrylate. Sections
were cut l0- thick and left unstained for fluorescent microsco-
py and, 5- thick to stain with Goldner's light microscopy.
Quantitative histomorphometry was done using an integrating
eyepiece with alternating hemispherical lines intersecting at 36
points with a grid. An eyepiece micrometer was used for
measurement of distances. Indices measured were: (1) trabecu-
lar bone volume as space occupied by mineralized and unminer-
alized trabecular bone tissue, as a fraction of whole bone tissue
(including marros); (2) osteoid volume as the fraction of unmin-
eralized bone matrix per unit of whole bone tissue including
marrow; (3) fractional osteoid surface as the fraction of trabecu-
lar bone surface covered by osteoid; (4) bone formation rate as
the volume of new bone formed per unit volume of pre-existing
bone per year, derived from the linear appositional rate, bone
volume, surface density and double-labeled surface. The equa-
tion is F Sv M Sfa where S, is mm2 trabecular surface area
per mm3 bone tissue, M is new bone per year and Sfa is mm2
double-labeled surface arealmm2 trabecular surface area [161;
(5) fractional resorption surface is the fraction of trabecular
bone surface occupied by Howships lacunae.
Yates' corrected x2 was used to compare frequency distribu-
tions between groups. Comparisons of biochemical and meta-
bolic findings were made with Student's t test for independent
samples. Pearson's r was computed in the correlational analy-
ses of biochemical values within a group. All calculations were
performed with the SPSS [17] or BMD-P [18] series of computer
programs.
Results
Relevant clinical data are summarized in Table 1. Biochemi-
cal and metabolic data are shown in Table 2. Diabetic patients
showed significantly lower serum calcium, albumin, and iPTH
Table 1. Clinical data in 28 nondiabetic (NDM) and 26 diabetic (DM)
patients
NDM DM
Male, number 20 19
Female, number 8 7
Age, years, mean SE
Time on dialysis, months, mean
32.5
SE 12.3
2.1
2.3
35.9 1.6
14.8 2.0
Table 2. Biochemical and metabolic data in 28 nondiabetic (NDM)
and 26 diabetic (DM) patients
NDM DM
Calcium, mg/dia 9.95 0.22 P < 0.05 9.38 0.16
Phosphorous, mgldl 4.69 0.30 5.68 0.43
Magnesium, mgldi 3.08 0.09 3.00 0.09
Alkaline P, lU/liter 94 17 96 13
Albumin, g/dl 4.6 0.11 P<0.002 4.1 0.1
iPTH, piEqimi 1733 271 P < 0.002 734 141
Calcitonin, pg/mi 303 59 301 31
a Values are reported as mean SEM.
Table 3. Radiologic axial skeletal survey in 28 nondiabetic (NDM) and
26 diabetic (DM) patients
NDM DM
Osteitis fibrosa, % 30 P < 0.03 0
Osteosclerosis, % 20 NS 0
Osteopenia, % 39 NS 41
than the nondiabetic patients. There was no correlation be-
tween serum albumin and calcium in either group. Serum iPTH
was not related to total serum calcium but was positively
correlated with serum phosphorous (r = 0.37, P < 0.05 in
nondiabetic patients and r = 0.54, P < 0.005 in diabetic
patients). iPTH levels correlated with alkaline phosphatase (r
0.59, P < 0.0009) and calcitonin (r = 0.51, P < 0.05) only in
nondiabetic patients. Vitamin D metabolites were measured in
the eight patients who had bone biopsies. Serum 25-hydroxyvi-
tamin D values ranged from undetectable to 30 ngjml (mean
SD = 14 10); four of eight patients had values within the range
of nutritional deficiency or less than 10 ng/ml. 1,25 dihydroxyvi-
tamin D values were 6 to 26 pg/ml (mean SD = 13 6); the
values were reduced in six of eight patients.
The results of the radiologic survey of the axial skeleton in
nondiabetic and diabetic patients are shown in Table 3. Specific
findings of secondary hyperparathyroidism, for example, oste-
itis fibrosa, were observed only in nondiabetic patients. The
relevant clinical and metabolic data from the eight patients who
underwent transilial bone biopsy at the time of renal transplan-
tation are shown on Table 4. The histologic appearance of
osteoporosis, decreased cellularity, and absence of deposition
of tetracycline was found in five of the eight patients. Only
patient 8 showed increased osteoclast numbers, resorption
surfaces, and excess osteoid consistent with the secondary
hyperparathyroidism seen in renal osteodystrophy. However,
this patient's bone volume was within the low normal range.
The numerical data of bone histomorphometry are given in
Table 5 [19] in order of increasing serum iPTH. The eight
patients showed either reduced (N = 5) or low normal (N = 3)
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Table 4. Clinical and biochemical data in eight uremic diabetic patients who underwent bone biopsy
Total
Time on calcium Magnesium Phosphorous
Patient Age dialysis iPTH Calcitonin 25(OH)D
no. years Sex months mg/di jsiEq/mi pg/mi ng/mi
l,25(OH)2D
pg/mi
1 41 M 8 8.9 2.5 2.3 124 235 8 11
2 32 F 10 9.1 3.1 3.7 160 235 8 9
3 43 M 0 9.5 2.1 1.8 184 115 25 18
4 35 F 18 9.0 3.7 5.8 258 315 10 11
5 53 M 8 8.7 3.2 4.0 385 174 18 26
6 34 M 7 10.0 2.9 3.6 550 263 U 14
7 43 M 6 9.0 3.8 2.6 1150 405 30 6
8 33 F 13 7.9 1.0 5.0 2090 145 10 9
Abbreviation: U, undetected.
Table 5. Measurements of bone histomorphometry in eight uremic diabetic patients
Diabetic patients (case number)a
Normalb 1 2 3 4 5 6 7 8
Trabecular bone volume (V) 0.21 0.04 0.12 0.11 0.14 0.12 0.12 0.17 0.19 0.18
mm3/mm3, mean SD
Osteoid volume (V0) mm3/mm3, 0.005 0.003 0 0.009 0.013 0.009 0.010 0.003 0.002 0.027
mean SEM
Fractional osteoid surface (Sf), 0.123 0.54 0 0.129 0.419 0.169 0.597 0.003 0.091 0.519
mm3/mm2, mean SD
Osteoid seam width, m, mean 6.9 6 0 7 9 11 7 0 7 19
SD
Bone formation rate, (F)c 0.15 — 0.25 0 0 0 0 0.085 0 0.005 0.697
mm3/mm3/yr
Fractional resorption surface, 0.063 0.025 0.029 0.008 0.017 0.011 0.024 0.238 0.094 0.294
(Sr)
Aluminum stain" + 0 0 + + + ND + + 0
a The patients are numbered according to the degree of secondary hyperparathyroidism as assessed by the serum iPTH level.
b Values were obtained from Meunier and Corupron [191.
Comparable normal data were not available; the normal range is estimated.
"Aluminum stain is reported qualitatively that is, 0, normal, + to +++, mild to severe, and ND, not done.
bone volume. Seven patients exhibited osteoid volume less than
normal, three an increase in fractional osteoid surface, and two
increased resorption surfaces. There was no relationship be-
tween any of the biochemical measurements and the morpho-
logic indices except for a correlation between serum PTH and
resorption surfaces (r = 0.81, P < 0.05).
The results of the staining of the biopsy sections for alumi-
num generously provided by Dr. Don Sherrard are found in
Table 5 and show no relationship to the other indices of bone
histomorphometry.
Discussion
This study demonstrates several unique features in the mani-
festations of secondary hyperparathyroidism in uremic diabetic
patients. We confirmed our earlier observations of lower circu-
lating iPTH in diabetic patients with endstage renal disease than
nondiabetic patients with comparable diseases and duration of
dialysis. The antiserum of the assay which we used in this study
was of a different specificity for PTH than the antiserum used in
our earlier report [9] and does not detect abnormal differences
in diabetic patients without renal disease [20]. Three other
immunoassays revealed lower values for the hormone in the
serum of diabetic patients with renal failure [10], during preg-
nancy [21], and in nonuremic insulin-treated diabetic patients
[22] than control subjects. Measurements of the endogenous
biologically active PTH through stimulation of adenylate cy-
clase in an in vitro bioassay [23] in the sera of eight diabetic
patients were similar to those of eight nondiabetic patients (Dr.
R. A. Nissenson, personal communication). The assay we used
detects primarily the carboxyl terminal end of the molecule,
including nonbiologically active fragments and, characteristi-
cally, shows increases from 10 to 200 times the upper limit of
normal in patients with chronic renal failure. Differences in the
metabolism of PTH between diabetic and nondiabetic patients
cannot be eliminated and need further study.
The reduced secondary hyperparathyroidism appears to be
unrelated to the course of diabetic nephropathy and length of
time on dialysis. Diabetic endstage renal disease is character-
ized by a relatively brief duration of renal failure associated
with proteinuria and hypertension [11]. Nondiabetic uremic
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Fig. 1. Trabecular bone volume (mm3/mm3 SD) in nonuremic control
subjects (N) and in renal osteodystrophy (ROD) in nondiabetic patients
(active and inactive) and diabetic patients (DM). Data on N were
obtained from Meunier and Corupron [191 and on ROD from Frost et al
[29], respectively.
control subjects for the biochemical indices were selected in
this study if their renal disease and clinical course were similar
to diabetic nephropathy. The two groups were closely matched
for age, sex, and duration of dialysis. Several biochemical
differences were noted between diabetic and nondiabetic ure-
mic patients. The serum calcium of diabetic patients was
significantly lower than nondiabetic patients. The absence of a
relationship between albumin and calcium in the serum of
diabetic patients suggests that the lower total serum calcium in
the diabetic patient is related to one or more factors regulating
serum calcium. These include retention of phosphate [241,
resistance of the skeleton to circulating PTH [25], nutritional
deficiency [261, or failure of renal hydroxylation of vitamin D
[27]. Neither 25-hydroxyvitamin D nor 1,25 dihydroxyvitamin
D are lower than normal in nonuremic diabetic patients [20].
The patients who had biopsies showed marked variation in their
nutritional status of vitamin D which did not appear to be
related to any biochemical or histomorphometric measurement,
and the I ,25-dihydroxy vitamin D values in this group were all
measurable and similar to values reported in patients with
endstage renal failure.
Despite the difference in secondary hyperparathyroidism
between diabetic and non-diabetic patients, serum alkaline
phosphatase was similar; however, alkaline phosphatase corre-
lated positively with PTH only in the nondiabetic patients. The
activity of this enzyme, as reported by other investigators, may
well reflect the severity of renal osteodystrophy in high bone
turnover states which tend to be more responsive to treatment
[28, 29]. The role of calcitonin in bone disease is not clear [30—.
32]. Modest increases in serum calcitonin levels were observed
in both diabetic and nondiabetic patients with chronic renal
failure and do not account for differences in bone morphology
between the two groups.
Radiologic assessment of the axial skeleton did not reveal
findings of osteitis fibrosa in diabetic patients, in contrast to
30% of the nondiabetic patients. Osteoscierosis, a marker of
severe secondary hyperparathyroidism, was similarly observed
only in nondiabetic patients. These data and our previous
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Fig. 2. Fractional osteoid surface (% sr) in nonuremic control
subjects (N) and in renal osteodystrophy (ROD) in nondiabetic patients
(active and inactive) and diabetic patients (DM). Data on N were
obtained from Meunier and Corupron [19] and on ROD from Frost et al
[19], respectively.
findings of decreased uptake in bone scans of uremic diabetic
patients indicate that diabetic patients with renal failure have
reduced manifestations of secondary hyperparathyroidism [9]
The main feature of the histology of bone in the diabetic
patients with chronic renal failure is the reduced or low normal
volume of bone associated with reduced indices of both bone
formation and resorption (Table 5). Only one patient whose
serum PTH concentration was 50 times the upper limit of
normal showed the more typical bone histology of secondary
hyperparathyroidism in endstage renal failure, for example,
increased osteoclastic resorption and an excess of unminera-
lized osteoid. A less typical aspect of this patient's bone
histology was the small amount of bone tissue. Although the
bond morphology in endstage renal failure is variable, most
patients show three types of osteodystrophy with the features
of osteomalacia or osteitis fibrosa predominating or mixed
which can be separated according to the dynamic measure-
ments of bone turnover and iPTH concentrations [33]. In
another series of patients in whom both the static and dynamic
indices of bone histology in dialysis patients are recorded, one-
third of the patients were reported to show 'inactive' renal
osteodystrophy, a variant of the osteomalacic form [29], char-
acterized by normal or increased bone volume, a mineralization
defect, increased osteoid volume, a low rate of bone turnover,
and normal or low concentrations of PTH. The diabetic patients
we studied differ from these patients, as illustrated in Figures 1
and 2, in the low volume of bone and the smaller amount of
osteoid. The paucity of osteoid tissue suggests that the osteo-
penia in diabetic bone is related to a decrease in matrix
synthesis. We do not, however, have serial measurements of
bone mass of diabetic patients on dialysis to document bone
loss, and techniques for direct quantitation of resorption rates
are not available. The static measures of resorption surface are
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unexpectedly low and not correlated with the rates of bone
formation in our study group. This reflects the limitations of
current methodology but also suggests uncoupling of the proc-
ess by which the integrity of the adult skeleton is maintained;
for example, activation of new remodeling sites initiated by
osteoclastic resorption followed by synthesis of matrix and
mineralization at the same site [34]. One explanation for our
findings is an uncoupling of this process associated with in-
creased bone loss of previously normal volume of bone, as
reported by DeLeeuw, Mulkens, and Vertommen in juvenile
diabetic patients [35]. Another possibility, consistent with an
earlier study of diabetic bone [7], is that bone volume was low
in our patients prior to renal failure and that the reduction in
bone turnover persists with the progression of renal failure.
Whether or not the changes in the bone of diabetic patients
with chronic renal failure can be attributed to the underlying
abnormality in glucose metabolism is uncertain. Evidence of
aluminum toxicity which has been incriminated in the etiology
of the inactive osteomalacic form of renal osteodystrophy [36,
37] was present in only two of six patients. Osteomalacia
associated with bone pain and hypercalcemia after vitamin D is
also reported to follow the surgery in 7% of patients on
maintenance dialysis treated by parathyroidectomy [38]. In
both these situations, however, there is abundant osteoid tissue
which is not calcified. This has led investigators to attribute the
hyperosteoidosis to a defect in mineralization rather than
matrix synthesis. The abnormality in the remodeling of diabetic
bone from the early studies of Frost and colleagues [7] reveals
reduced rates of bone formation and resorption. He and his
coworkers found the ratio of resorption spaces to the number of
osteoid seams to be higher in diabetic rib lamelar bone than in
nondiabetic bone, suggesting that diabetic bone was more
slowly remodeled. There is considerable evidence that the
skeleton of the diabetic patient contains less mineral than that
of nondiabetic patients [1—5, 39]. However, osteomalacia, os-
teoporosis, or increased fragility of diabetic bone is not well-
documented [2, 8]. These observations favor the view that the
bone of diabetic patients has a reduced rate of metabolism
which influences the 'response' to chronic renal failure. That
the defect in bone cells in diabetic patients is common to the
cells of the parathyroid, resulting in reduced secretion of the
hormone, is entirely speculative. Since most of our patients
were insulin-dependent juvenile onset diabetic patients, treated
with insulin for many years, deficiency of this hormone is an
unlikely explanation for our findings.
The clinical relevance of these findings is complex. How do
patients with diabetes mellitus and pre-existing osteopenia fare
with the progression of renal failure? There may be short-term
benefits from low bone turnover and reduction in the concentra-
tion of circulating PTH in the uremic diabetic patient. They
exhibit few, if any, manifestations of secondary hyperpara-
thyroidism and have a reduced risk of aseptic necrosis following
kidney transplantation [9]. In contrast to these short-term
benefits, the long-term consequences of the bone disease we
have described is disconcerting. The low bone volume and low
bone turnover in a disease which promotes increased resorption
of bone may lead to skeletal collapse (patient 4 in Tables 4 and 5
refused dialysis and died 3 months after returning to hemodialy-
sis following a failed kidney transplant partly because of the
complications of multiple fractures). The results of our study
and reports of bone disease following parathyroidectomy [38]
mandate against parathyroidectomy in uremic diabetic patients.
As diabetic patients are maintained on dialysis or with kidney
transplantation, the impact of uremia on the diabetic skeleton
will be better understood. In the interim serial monitoring of
bone mass with bone densitometry or bone biopsy could be
useful in the management of the individual diabetic patient with
endstage renal disease. Additional studies will be needed to
indicate which of the current therapies of uremia is least
detrimental to the skeleton of the diabetic patient.
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